The American College of Cardiology (ACC), the American Heart Association (AHA) and nine other medical organizations released updated dyslipidemia guidelines replacing the 2018 AHA/ACC cholesterol guidance. The revision reflects growing evidence that atherogenic particles beyond LDL-C—including triglyceride-rich remnant particles and lipoprotein(a) (Lp(a))—contribute meaningfully to atherosclerotic cardiovascular disease (ASCVD).
Key principles
– Much cardiovascular disease is preventable; elevated LDL remains a major modifiable risk factor.
– Lifestyle optimization is still the foundation of prevention (healthy diet, regular physical activity, weight management, smoking cessation, and blood pressure control).
– The guidance encourages earlier consideration of lipid-lowering medication when lipid levels remain above goal after lifestyle changes, on the premise that lowering LDL sooner and keeping it low over time reduces lifetime exposure to harmful lipids and lowers heart attack and stroke risk.
Scope and emphasis
– The new document consolidates evidence-based recommendations for assessing and treating multiple blood lipids with the goal of reducing ASCVD.
– There is renewed emphasis on early detection of hyperlipidemia, clearer LDL-C targets, and tailoring treatment based on an individual’s lifetime risk.
– Reintroducing specific LDL targets is intended to make treatment decisions more actionable for clinicians and patients.
Risk assessment: PREVENT-ASCVD
– The guideline committee recommends using the AHA PREVENT-ASCVD equations for primary prevention risk estimation.
– These calculators provide contemporary estimates of 10- and 30-year risk of myocardial infarction and stroke for adults aged 30–79 who do not have known ASCVD or subclinical atherosclerosis and who meet specified LDL criteria.
– PREVENT-ASCVD uses routine clinical data (cholesterol values, blood pressure, age, smoking status, etc.) and permits incorporation of “risk enhancers” to individualize risk estimates and guide decisions about initiating lipid-lowering therapy.
Selective additional testing to refine risk
When results would change management, the guidelines recommend considering selective tests:
– Coronary artery calcium (CAC) scan (non-contrast): useful to detect subclinical calcified plaque and to inform statin decisions in adults where risk is uncertain.
– Lipoprotein(a) [Lp(a)]: a one-time measurement in adulthood is advised because levels are largely genetic and stable; elevated Lp(a) is an independent ASCVD risk factor.
– Apolipoprotein B (apoB): helpful for evaluating residual ASCVD risk and guiding therapy in people with cardiometabolic disease, type 2 diabetes, high triglycerides, or established CVD who have reached LDL-C and non-HDL-C goals.
Treatment approach
– Reinforce lifestyle changes as the first-line strategy.
– If LDL-C remains above target after lifestyle measures, clinicians should consider earlier initiation of statin therapy than was typical previously, with an aim of achieving and maintaining lower LDL levels over time.
– For patients who do not reach LDL goals with lifestyle and statins, the guidance supports adding non-statin therapies to attain targets.
– The recommendations move away from one-size-fits-all care toward integration of clinical factors, imaging, and biomarkers to personalize prevention strategies.
Bottom line
The updated guidelines shift emphasis toward earlier detection, clearer LDL targets, and personalized yet structured prevention. By identifying risk sooner, using selective testing to refine risk, and aiming for sustained lower LDL-C over a lifetime, clinicians can more effectively reduce a patient’s lifetime risk of ASCVD.
